Marwa Tarek

Marwa Tarek

Auto-generated profile, based on publicly available information

Marwa Tarek

Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2016 in Immunotherapy
Verified
Journal Article
Closed access
MAMahmoud A Ali
Mahmoud A Ali
marwa matbolimarwa matboli
marwa matboli
MTMarwa Tarek
Marwa Tarek
MRMaged Reda
Maged Reda
KKKamal M Kamal
Kamal M Kamal
OAOmar Abdel-Rahman
Omar Abdel-Rahman
Epigenetic changes in oncogenes and tumor-suppressor genes contribute to carcinogenesis. Understanding the epigenetic and genetic components of tumor immune evasion is crucial. Few cancer genetic mutations have been linked to direct correlations with immune evasion. Studies on the epigenetic modulation of the immune checkpoints have revealed a critical interaction between epigenetic and immune modulation. Epigenetic modifiers can activate many silenced genes. Some of them are immune checkpoints regulators that turn on immune responses and others turn them off resulting in immune evasion. Many forms of epigenetic inheritance mechanisms may play a role in regulation of immune checkpoints including: covalent modifications, noncoding RNA and histone modifications. In this review, we will show how the potential interaction between epigenetic and immune modulation may lead to new approaches for specific epigenome/immunome-targeted therapies for cancer.

10 January 2014 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
RARanda Ali‐Labib
Randa Ali‐Labib
MLManal Louis Louka
Manal Louis Louka
IGIman Hassan El‐Sayed Galal
Iman Hassan El‐Sayed Galal
MTMarwa Tarek
Marwa Tarek

1 May 2017 in Tumor Biology
Verified
Journal Article
Open access
MTMarwa Tarek
Marwa Tarek
MLManal Louis Louka
Manal Louis Louka
EKEman Khairy
Eman Khairy
RARanda Ali-Labib
Randa Ali-Labib
DZDoaa Zakaria Zaky
Doaa Zakaria Zaky
IMIman F Montasser
Iman F Montasser
There is an obvious need to diagnose hepatocellular carcinoma using novel non-invasive and sensitive biomarkers. In this regard, the aim of this study was to evaluate and correlate both relative quantification of microRNA-7 using quantitative real time polymerase chain reaction and quantitative analysis of selenoprotein P using enzyme-linked immunosorbent assay in sera of hepatocellular carcinoma patients, chronic liver disease patients, as well as normal healthy subjects in order to establish a new diagnostic biomarker with a valid non-invasive technique. In addition, this study aimed to investigate whether changes in selenium supply affect microRNA-7 expression and selenoprotein P levels in human hepatocarcinoma cell line (HepG2). The results showed a highly significant decrease in serum microRNA-7 relative quantification values and selenoprotein P levels in malignant group in comparison with benign and control groups. The best cutoff for serum microRNA-7 and selenoprotein P to discriminate hepatocellular carcinoma group from benign and control groups was 0.06 and 4.30 mg/L, respectively. Furthermore, this study showed that changes in selenium supply to HepG2 cell line can alter the microRNA-7 profile and are paralleled by changes in the concentration of its target protein (selenoprotein P). Hence, serum microRNA-7 and selenoprotein P appear to be potential non-invasive diagnostic markers for hepatocellular carcinoma. Moreover, the results suggest that selenium could be used as an anticancer therapy for hepatocellular carcinoma by affecting both microRNA-7 and selenoprotein P.

18 February 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
NANashwah Attallah
Nashwah Attallah
AKAmal Kabbash
Amal Kabbash
Walaa A. NegmWalaa A. Negm
Walaa A. Negm
Engy ElekhnawyEngy Elekhnawy
Engy Elekhnawy
RBReem Binsuwaidan
Reem Binsuwaidan
HFheba fawzy
heba fawzy
Diseases and infections of the respiratory tract are common global causes of morbidity and mortality. Our study attempts to elucidate a novel remedy for respiratory ailments, in addition to identifying and quantifying the metabolites of Saussurea costus root extract (SCRE) using HPLC. Then, in vitro antiviral and in vivo lung protective effects were elucidated. The in vitro antiviral potential of SCRE was analyzed via plaque assay against the low pathogenic human coronavirus (HCoV-229E) and human influenza virus (H1N1). The value of the half maximal inhibitory concentrations (IC50) of SCRE against HCoV-229E and H1N1 influenza virus were 23.21 ± 1.1 and 47.6 ± 2.3 µg/mL, respectively. SCRE showed a histological improvement, namely a decrease in inducible nitric oxide synthase (iNOS) and caspase-3 immunoexpression in in vivo cyclophosphamide (CP)-induced acute lung injury (ALI). Moreover, there was a considerable decline in microRNA-let-7a gene expression and a significant rise in heme oxygenase-1 (HO-1) gene expression, with a marked decrease in the malondialdehyde (MDA) level. Molecular docking studies revealed that the major constituents of SCRE have a good affinity for caspase-3, HO-1, and iNOS proteins. In conclusion, a traditional plant SCRE could be a promising source of novel therapeutic agents for treating and protecting respiratory tract diseases. More future investigations should be carried out to reveal its efficacy clinically.

21 December 2023 in Gene
Verified
Journal Article
Closed access
SSSara Gamal Sherif
Sara Gamal Sherif
MTMarwa Tarek
Marwa Tarek
YSYasmine Gamal Sabry
Yasmine Gamal Sabry
AGAzza Hassan Abou Ghalia
Azza Hassan Abou Ghalia

30 September 2024 in Egyptian Journal of Medical Human Genetics
Verified
Journal Article
Open access
PDF file
TAToulin Mohamed Abdelaziz Albostany
Toulin Mohamed Abdelaziz Albostany
MTMarwa Tarek
Marwa Tarek
SASherihan Adel
Sherihan Adel
MIMaha Imam
Maha Imam
RERasha El-Owaidy
Rasha El-Owaidy
MAManal Basyouni Ahmed
Manal Basyouni Ahmed
Background and objectives: Lupus nephritis (LN) is a severe clinical manifestation seen in individuals with systemic lupus erythematous (SLE). It has a poor long-term prognosis in pediatric patients with high morbidity and mortality rates. MicroRNAs (miRNAs) are noncoding small RNAs that act as epigenetic modulators, regulating gene expression, and modulating the understanding of mechanisms and pathogenesis of human diseases. Depending on bioinformatics analysis, we aimed to investigate urinary expression of miR-663a in LN among SLE children and discriminate between proteinuria of LN versus chronic renal disease without SLE. Methods: The urinary miR-663a expression levels were estimated in cellular pellets from 15 SLE patients, 15 SLE and biopsy-proven active LN patients, 15 chronic kidney disease (CKD) patients rather than LN and 15 healthy controls. Results: LN patients had significantly higher urinary miR-663a expression levels compared to other groups (p < 0.0001). Urinary miR-663a at a cutoff of 8.61 had a diagnostic value of 93.3% for LN among pediatric SLE with 100% specificity (p < 0.0001). Moreover, miR-663a was upregulated in advanced grades and LN classes V, IV, and III compared to class II. Furthermore, miR-663a was positively correlated with the duration of SLE, activity index, chronicity index, urinary protein, anti-dsDNA, and SLEDAI score, and negatively correlated with serum complement C3 (p < 0.05). Conclusion: miR-663a could be related to the pathogenesis of kidney damage in LN; that could provide a specific noninvasive diagnostic and follow -up tool for LN patients.